Online inquiry

IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12900MR)

This product GTTS-WQ12900MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FZD10 gene. The antibody can be applied in Synovial sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_007197.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 11211
UniProt ID Q9ULW2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12900MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ982MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ5189MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ10081MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ8142MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ9457MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ9365MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ6251MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ9420MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW